Shares of other companies:
April 29, 2024 Tesla, Baidu Join Forces for Self-Driving Tech in China
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
April 26, 2024 Top 10 High Dividend Yield Stocks
Tesla Q1: Facing A Liquidity Crunch; Dilution Ahead?
April 29, 2024
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
NVS Stock News and Mentions of Novartis AG Stocktwits
Updated: April 30, 2024 (07:17)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Novartis AG Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Novartis AG (NVS).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Novartis AG stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Novartis AG (NVS)
April 29, 2024 (16:36) / "Benzinga" (by Vandana Singh)
MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib - MorphoSys ( NASDAQ:MOR ) , Novartis ( NYSE:NVS )
MorphoSys AG MOR is reportedly facing a burgeoning safety concern surrounding pelabresib, an experimental myelofibrosis treatment. Myelofibrosis is a type of blood cancer characterized by the buildup of scar tissue, called "fibrosis," in the bone marrow.
In Article Trend: Neutral
April 24, 2024 (13:36) / "Zacks Commentary" (by Zacks Equity Research)
April 24, 2024 (13:19) / "Zacks Commentary" (by Ahan Chakraborty)
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.
In Article Trend: Somewhat-Bullish
April 23, 2024 (19:05) / "Benzinga" (by Vandana Singh)
FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors - Novartis ( NYSE:NVS )
Tuesday, Novartis AG NVS received FDA approval for its Lutathera ( lutetium Lu 177 dotatate / INN: lutetium ( 177Lu ) oxodotreotide ) for pediatric patients 12 years and older with somatostatin receptor-positive ( SSTR+ ) gastroenteropancreatic neuroendocrine tumors ( GEP-NETs ) , including ...
In Article Trend: Somewhat-Bullish
April 23, 2024 (13:44) / "Zacks Commentary" (by Zacks Equity Research)
Incyte ( INCY ) to Report Q1 Earnings: What's in the Cards?
Incyte's (INCY) first-quarter 2024 revenues are likely to have been driven by the U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.
In Article Trend: Somewhat-Bullish
April 23, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Novartis ( NVS ) Q1 Earnings, Sales Beat, Guidance Raised
Novartis (NVS) comfortably beats first-quarter earnings and sales estimates. The company ups its outlook for 2024 on strong growth across key brands.
In Article Trend: Somewhat-Bullish
April 23, 2024 (12:57) / "Zacks Commentary" (by Zacks Equity Research)
The Zacks Analyst Blog Highlights Novartis, American Express, ConocoPhillips, Netflix and Schlumberger
Novartis, American Express, ConocoPhillips, Netflix and Schlumberger are part of the Zacks top Analyst Blog.
In Article Trend: Somewhat-Bullish
April 23, 2024 (12:25) / "Benzinga" (by Vandana Singh)
Why Is Novartis Stock Trading Higher On Tuesday? - Novartis ( NYSE:NVS )
Shares of Swiss pharma giant Novartis AG NVS after the company raised its full-year guidance following better-than-expected first-quarter results. Novartis reported first-quarter adjusted EPS of $1.80, up 17% year over year ( 23% on constant currency ) , beating the consensus of $1.67.
In Article Trend: Somewhat-Bullish
April 23, 2024 (10:55) / "Benzinga" (by Shanthi Rexaline)
S&P 500, Nasdaq Futures Climb Higher: Will Tesla Earnings Spark Rally Or Retreat? - Invesco QQQ Trust, Series 1 ( NASDAQ:QQQ ) , SPDR S&P 500 ( ARCA:SPY )
The mood on Wall Street turned tentative on Tuesday as investors awaited earnings reports from the "Magnificent 7," companies that fueled much of the market's upside since 2023. Index futures rose slightly in early trading. Asian markets closed mostly higher, while European markets started on a ...
In Article Trend: Somewhat-Bullish
April 23, 2024 (05:00) / "GlobeNewswire" (by Novartis Pharma AG)
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
Ad hoc announcement pursuant to Art. 53 LR ...
In Article Trend: Somewhat-Bullish
April 21, 2024 (21:45) / "Benzinga" (by Shanthi Rexaline)
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week - Invesco QQQ Trust, Series 1 ( NASDAQ:QQQ ) , SPDR S&P 500 ( ARCA:SPY )
As the market runs into rough weather, the importance of the upcoming week's earnings cannot be emphasized enough. A lot is riding on the earnings reports of companies like Tesla, Inc. TSLA, Meta Platforms, Inc. META, Microsoft Corp. MSFT and Alphabet, Inc. GOOGL ( GOOG ) .
In Article Trend: Neutral
April 19, 2024 (14:10) / "Zacks Commentary" (by Ekta Bagri)
Novartis ( NVS ) to Report Q1 Earnings: What to Expect?
Novartis (NVS) key drugs Entresto, Kisqali and Pluvicto are likely to have fueled its top and bottom-line numbers in the first quarter.
In Article Trend: Somewhat-Bullish
April 18, 2024 (21:31) / "PR Newswire" (by DelveInsight Business Research)
Global Radioimmunoassay Market to Grow at a Minimal CAGR of ~3% by 2030 | DelveInsight
The increasing need for radioimmunoassay is mainly driven by the rising occurrence of cancer, infectious diseases, and various other health conditions, along with a growing number of epidemics and pandemics and increasing health awareness.
In Article Trend: Neutral
April 17, 2024 (15:48) / "Benzinga" (by Vandana Singh)
Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years - Novartis ( NYSE:NVS )
Novartis AG NVS released data from the ALITHIOS open-label extension study showing sustained efficacy of first-line, continuous Kesimpta ( ofatumumab ) treatment for up to six years in recently diagnosed relapsing multiple sclerosis.
In Article Trend: Neutral
April 17, 2024 (13:50) / "Benzinga" (by Globe Newswire)
Continuous Manufacturing Market Size is expected to reach USD 1,420.95 million by 2031, growing at a CAGR of 12.2%: Straits Research
New York, United States, April 17, 2024 ( GLOBE NEWSWIRE ) -- Continuous manufacturing is distinguished from batch manufacturing, which entails production execution in discrete steps separated by intervals by the uninterrupted feeding of raw materials into a manufacturing system and the ...
In Article Trend: Somewhat-Bullish
April 16, 2024 (18:25) / "Benzinga" (by Vandana Singh)
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades - Avalo Therapeutics ( NASDAQ:AVTX )
Tuesday, Oppenheimer upgraded Avalo Therapeutics Inc AVTX, noting that its AVTX-009 is a promising drug candidate and looks forward to a Phase 2 topline data in 2026 in hidradenitis suppurativa ( HS ) and additional updates.
In Article Trend: Somewhat-Bullish
April 16, 2024 (13:06) / "Zacks Commentary" (by Zacks Equity Research)
Novartis ( NVS ) Presents Positive Data on Rare Kidney Disease Drug
Novartis (NVS) announces encouraging data on Fabhalta from a phase III study for the treatment for the treatment of immunoglobulin A nephropathy, a heterogeneous, progressive, rare kidney disease.
In Article Trend: Somewhat-Bullish
April 11, 2024 (12:14) / "The Financial Express" (by Health Desk)
Novartis enters into licensing deal for Arvinas' cancer drug worth up to $1.01 billion
Swiss drugmaker Novartis AG has entered into a licensing deal worth up to $1.01 billion with Arvinas. According to a report by news agency Reuters, the deal has been signed to gain access to the U.S. biotech firm's experimental prostate cancer drug.
In Article Trend: Neutral
April 11, 2024 (08:20) / "GlobeNewswire" (by Novartis Pharma AG)
Novartis tender offer for MorphoSys AG commences
Basel, April 11, 2024 - Novartis published today the offer document for the voluntary public takeover offer by its wholly owned subsidiary Novartis BidCo AG for all outstanding shares of MorphoSys AG ( "MorphoSys" ) , including all shares represented by MorphoSys American Depositary Shares ( the ...
In Article Trend: Somewhat-Bullish
April 10, 2024 (19:07) / "Benzinga" (by Vandana Singh)
Why Is Alpine Immune Sciences Stock Trading Higher Today? - Alpine Immune Sciences ( NASDAQ:ALPN )
Alpine Immune Sciences Inc ALPN is reportedly considering strategic options, including a potential sale, following interest from potential buyers. The Seattle-based firm is working closely with advisors and evaluating various possibilities, and at least one major pharmaceutical player has ...
In Article Trend: Somewhat-Bullish
April 9, 2024 (16:33) / "Benzinga" (by Nabaparna Bhattacharya)
Novartis To Axe 680 Development Jobs Amid Global Reshuffle: Report - Novartis ( NYSE:NVS )
Novartis AG NVS reportedly plans to slash up to 680 positions in its development organization, aiding in drug market launches. The Basel-based company announced that approximately 440 positions will be cut in Switzerland and up to 240 in the U.S. within the next two to three years, Reuters reported.
In Article Trend: Somewhat-Bullish
April 8, 2024 (18:19) / "Benzinga" (by Vandana Singh)
Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population - Legend Biotech ( NASDAQ:LEGN ) , Johnson & Johnson ( NYSE:JNJ )
Friday, the FDA approved Johnson & Johnson JNJ Carvykti ( ciltacabtagene autoleucel; cilta-cel ) for relapsed or refractory multiple myeloma patients who have received at least one prior line of therapy and are refractory to lenalidomide.
In Article Trend: Somewhat-Bullish
April 4, 2024 (18:09) / "Benzinga" (by Vandana Singh)
Why Is Novartis Stock Trading Higher On Thursday? - Novartis ( NYSE:NVS )
Thursday, Novartis AG NVS shares are trading higher after the company confirmed plans to file for Pluvicto pre-taxane label expansion in the second half of 2024 based on data from its Phase 3 PSMAfore study.
In Article Trend: Somewhat-Bullish
April 4, 2024 (14:55) / "Benzinga" (by Globe Newswire)
Alpha Emitter Market Size is projected to reach USD 601.59 million by 2031, growing at a CAGR of 13.67%: Straits Research
New York, United States, April 04, 2024 ( GLOBE NEWSWIRE ) -- Alpha emitters are substances emitted by radioactive sources that decay after releasing alpha particles. They achieve the appropriate biodistribution and related dose distribution to provide successful therapy without producing severe ...
In Article Trend: Neutral
April 1, 2024 (12:00) / "GlobeNewswire" (by NewAmsterdam Pharma N.V)
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
NAARDEN, the Netherlands and MIAMI, April 01, 2024 ( GLOBE NEWSWIRE ) -- NewAmsterdam Pharma Company N.V. ( Nasdaq: NAMS or "NewAmsterdam" or the "Company" ) , a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ( ...
In Article Trend: Somewhat-Bullish
April 1, 2024 (11:00) / "PR Newswire" (by Carisma Therapeutics Inc.)
Carisma Therapeutics Announces Changes to its Board of Directors
PHILADELPHIA, April 1, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. ( Nasdaq: CARM ) ( "Carisma" or the "Company" ) , a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of John Hohneker, M.D. to the Board ...
In Article Trend: Somewhat-Bullish
March 28, 2024 (19:22) / "GlobeNewswire" (by AVEO Pharmaceuticals)
CORRECTION - AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
- Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer ...
In Article Trend: Somewhat-Bullish
March 27, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Is WisdomTree International Hedged Quality Dividend Growth ETF ( IHDG ) a Strong ETF Right Now?
Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
March 26, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Is Vanguard International Dividend Appreciation ETF ( VIGI ) a Strong ETF Right Now?
Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
March 25, 2024 (12:10) / "GlobeNewswire" (by Inc.)
AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
- Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer ...
In Article Trend: Somewhat-Bullish
March 25, 2024 (12:10) / "Benzinga" (by Globe Newswire)
AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
- Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer - - Formation of a Scientific Advisory Committee from world-renowned cancer institutions -
In Article Trend: Somewhat-Bullish
March 22, 2024 (16:18) / "PR Newswire"
Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... - PR Newswire
Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... PR ...
In Article Trend: Somewhat-Bullish
March 20, 2024 (10:00) / "GlobeNewswire" (by BioNTech SE)
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
Mainz, Germany, March 20, 2024 ( GLOBE NEWSWIRE ) - BioNTech SE ( Nasdaq: BNTX, "BioNTech" or "the Company" ) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer effective July 1, 2024.
In Article Trend: Somewhat-Bullish
March 19, 2024 (18:16) / "Benzinga" (by Vandana Singh)
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform - Voyager Therapeutics ( NASDAQ:VYGR )
H.C. Wainwright initiated coverage on Voyager Therapeutics Inc VYGR, noting a growing franchise of novel, highly-differentiated adeno-associated virus ( AAV ) -based TRACER capsids with the potential to overcome limitations of central nervous system ( CNS ) delivery and systemic toxicity of ...
In Article Trend: Somewhat-Bullish
March 18, 2024 (09:36) / "PR Newswire"
Gene therapy market size to grow by USD 4.61 billion from 2022 to 2027, North America is estimated to contribute 39 ... - PR Newswire
Gene therapy market size to grow by USD 4.61 billion from 2022 to 2027, North America is estimated to contribute 39 ... PR ...
In Article Trend: Somewhat-Bullish
March 15, 2024 (17:01) / "Benzinga" (by Vandana Singh)
FDA Approves BeiGene's First Drug Candidate Produced Through Its Immuno-Oncology Program For Esophageal Cancer - BeiGene ( NASDAQ:BGNE )
On Thursday, the FDA approved BeiGene Ltd's BGNE approved Tevimbra ( tislelizumab-jsgr ) as monotherapy for adult patients with unresectable or metastatic esophageal squamous cell carcinoma ( ESCC ) after prior systemic chemotherapy that did not include a PD- ( L ) 1 inhibitor.
In Article Trend: Somewhat-Bullish
March 15, 2024 (14:30) / "PR Newswire" (by MarketsandMarkets)
Monoclonal Antibody ( mABs ) Therapeutics Market Worth $497.5 billion | MarketsandMarkets™
CHICAGO, March 15, 2024 /PRNewswire/ -- Monoclonal Antibody ( mABs ) Therapeutics Market in terms of revenue was estimated to be worth $252.6 billion in 2024 and is poised to reach $497.5 billion by 2029, growing at a CAGR of 14.5% from 2024 to 2029 according to a new report by ...
In Article Trend: Somewhat-Bullish
March 14, 2024 (14:15) / "Benzinga" (by Globe Newswire)
Actinic Keratosis Treatment Market Size is projected to reach USD 9.22 billion by 2031, growing at a CAGR of 4.1%: Straits Research
New York, United States, March 14, 2024 ( GLOBE NEWSWIRE ) -- The purpose of treating actinic keratosis, a skin condition induced by prolonged sun exposure, is to prevent these precancerous lesions from developing into skin cancer.
In Article Trend: Neutral
March 12, 2024 (15:30) / "Benzinga" (by Globe Newswire)
Pheochromocytoma Industry Shows Steady Growth Trajectory, Reaching $3.56 Billion In 2028 As Per The Business Research Company's Pheochromocytoma Global Market Report 2024
LONDON, March 12, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Pheochromocytoma Global Market Report 2024, the pheochromocytoma market has been steadily expanding in recent years, with a projected growth from $2.89 billion in 2023 to $3.03 billion in 2024, reflecting a ...
In Article Trend: Bullish
March 12, 2024 (14:20) / "Benzinga" (by Globe Newswire)
Global Contraceptive Drugs Market Size is Projected to Reach USD 28.96 billion by 2030, Growing at a CAGR of 7.3%: Straits Research - Agile Therapeutics ( NASDAQ:AGRX ) , GSK ( NYSE:GSK )
New York, United States, March 12, 2024 ( GLOBE NEWSWIRE ) -- Contraception encompasses the use of drugs to prevent pregnancy, the transmission of sexually transmitted diseases ( STDs ) , the transmission of sexually transmitted infections ( STIs ) , family planning, and birth control.
In Article Trend: Somewhat-Bullish
March 11, 2024 (14:38) / "Benzinga" (by Piero Cingari)
Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach' - AstraZeneca ( NASDAQ:AZN ) , ASML Holding ( NASDAQ:ASML )
Goldman Sachs has flagged an increasing concern over the U.S. stock market's heavy concentration and the dominant sway of its largest tech stocks, urging investors to broaden their geographical diversification.
In Article Trend: Neutral
March 8, 2024 (11:20) / "Zacks Commentary" (by Zacks Equity Research)
Is Nuveen ESG International Developed Markets Equity ETF ( NUDM ) a Strong ETF Right Now?
Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
March 7, 2024 (23:30) / "PR Newswire" (by Research and Markets)
Global Dilated Cardiomyopathy ( DCM ) Market Report 2024, with Company Profiles of the Top 10 Major Market Players
DUBLIN, March 7, 2024 /PRNewswire/ -- The "Global Dilated Cardiomyopathy Market by Drug Class Inhibitors, Treatment Type, Route of Administration, Distribution Channel, and By Region" report has been added to ResearchAndMarkets.com's offering.
In Article Trend: Somewhat-Bullish
March 7, 2024 (11:20) / "Zacks Commentary" (by Zacks Equity Research)
Is WisdomTree International Equity ETF ( DWM ) a Strong ETF Right Now?
Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
March 5, 2024 (21:45) / "Benzinga" (by Natan Ponieman)
Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic - AstraZeneca ( NASDAQ:AZN ) , Bristol-Myers Squibb ( NYSE:BMY )
As President Joe Biden prepares for his State of the Union address on Thursday, he's expected to touch on several key issues including Bidenomics, access to healthcare and the U.S.' role in the world.
In Article Trend: Neutral
March 4, 2024 (16:34) / "Benzinga" (by Vandana Singh)
Novartis Reveals Promising Gene Therapy Data for Treating Spinal Muscular Atrophy in Older Children - Novartis ( NYSE:NVS )
Monday, Novartis AG NVS presented new data for Zolgensma ( onasemnogene abeparvovec ) , a one-time gene therapy for the treatment of spinal muscular atrophy ( SMA ) .
In Article Trend: Neutral
March 4, 2024 (06:15) / "GlobeNewswire" (by Novartis Pharma AG)
Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA
Basel, March 4, 2024 - Novartis today presented new data that continue to support the clinical benefits of Zolgensma® ( onasemnogene abeparvovec ) , the only one-time gene therapy for the treatment of spinal muscular atrophy ( SMA ) .
In Article Trend: Neutral
Related stocks from Healthcare sector
Aridis Pharmaceuticals, Inc. (ARDS)
Palatin Technologies, Inc. (PTN)
Align Technology, Inc. (ALGN)
Cutera, Inc. (CUTR)
Zymeworks Inc. (ZYME)
MediciNova, Inc. (MNOV)
Zynerba Pharmaceuticals, Inc. (ZYNE)
Kiniksa Pharmaceuticals, Ltd. (KNSA)
Inspira Technologies Oxy B.H.N. Ltd. (IINN)
Alpine Immune Sciences, Inc. (ALPN)
This website uses cookies to ensure you get the best experience on our website